Porous EH and EH-PEG scaffolds as gene delivery vehicles to skeletal muscle.
OBJECTIVE
Synthetic biomaterials are widely used in an attempt to control the cellular behavior of regenerative tissues. This can be done by altering the chemical and physical properties of the polymeric scaffold to guide tissue repair. This paper addresses the use of a polymeric scaffold (EH network) made from the cyclic acetal monomer, 5-ethyl-5-(hydroxymethyl)-β,β-dimethyl-1,3-dioxane-2-ethanol diacrylate (EHD), as a release device for a therapeutic plasmid encoding for an insulin-like growth factor-1 green fluorescent protein fusion protein (IGF-1 GFP).


METHODS
Scaffolds were designed to have different porous architectures, and the impact of these architectures on plasmid release was determined. We hypothesized that IGF-1 could be delivered more effectively using a porous scaffold to allow for the release of IGF-1.


RESULTS
We showed that by altering the number of pores exposed to the surface of the network, faster plasmid loading and release were achieved. In addition, the IGF-1 GFP plasmids were found to be effective in producing IGF-1 and GFP within human skeletal muscle myoblast cell cultures.


CONCLUSIONS
This work aims to show the utility of EH biomaterials for plasmid delivery for potentially localized skeletal muscle regeneration.
Department of Chemical and Biomolecular Engineering, University of Maryland, College Park, Maryland 20742, USA.
Erin E
EE
Falco
Martha O
MO
Wang
Joshua A
JA
Thompson
Joshua M
JM
Chetta
Diana M
DM
Yoon
Erik Z
EZ
Li
Mangesh M
MM
Kulkami
Sameer
S
Shah
Abhay
A
Pandit
J Scott
JS
Roth
John P
JP
Fisher
D000179:Acrylates / Q000737:chemistry*; D001672:Biocompatible Materials / Q000138:chemical synthesis; D002478:Cells, Cultured; D004337:Drug Carriers / Q000138:chemical synthesis / Q000627:therapeutic use; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods; D049452:Green Fluorescent Proteins / Q000008:administration & dosage / Q000737:chemistry; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000008:administration & dosage*; D018482:Muscle, Skeletal / Q000378:metabolism / Q000502:physiology*; D032448:Myoblasts, Skeletal / Q000187:drug effects / Q000378:metabolism; D010957:Plasmids / Q000008:administration & dosage / Q000235:genetics; D011108:Polymers / Q000138:chemical synthesis; D016062:Porosity; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000737:chemistry; D012038:Regeneration; D023822:Tissue Engineering / Q000379:methods; D054457:Tissue Scaffolds / Q000737:chemistry*
C528557:5-ethyl-5-(hydroxymethyl)-beta,beta-dimethyl-1,3-dioxane-2-ethanol diacrylate; D000179:Acrylates; D001672:Biocompatible Materials; D004337:Drug Carriers; D011108:Polymers; D011993:Recombinant Fusion Proteins; D049452:Green Fluorescent Proteins; D007334:Insulin-Like Growth Factor I
Fundam Clin Pharmacol. 2006 Feb;20(1):81-9
16448398
Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1206-10
14745025
Trends Biotechnol. 1999 Aug;17(8):335-40
10407406
J Appl Physiol (1985). 1998 May;84(5):1716-22
9572822
Nat Rev Genet. 2003 May;4(5):346-58
12728277
Biochem Biophys Res Commun. 2000 May 27;272(1):230-5
10872832
Med Device Technol. 2005 Apr;16(3):12-4
15871417
Biotechnol Appl Biochem. 2007 Feb;46(Pt 2):73-84
17227284
J Surg Res. 2008 Sep;149(1):76-83
18395749
Exp Biol Med (Maywood). 2007 Dec;232(11):1477-87
18040073
Trends Immunol. 2005 Oct;26(10):535-42
16109502
Artif Organs. 1995 May;19(5):458-67
7625927
Eur Cell Mater. 2003 Jun 30;5:29-39; discussion 39-40
14562270
J Biol Chem. 1985 Dec 15;260(29):15892-8
2999143
Am J Physiol. 1990 Jul;259(1 Pt 1):E89-95
2372054
Molecules. 2005 Jan 31;10(1):65-80
18007277
Tissue Eng Part B Rev. 2009 Jun;15(2):201-14
19249942
Acta Physiol Scand. 1999 Dec;167(4):301-5
10632630
J Biomed Mater Res A. 2008 Sep;86(3):662-70
18022839
Pharm Res. 2008 Oct;25(10):2348-56
18536870
Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15603-7
9861016
J Biomed Mater Res A. 2007 Jun 1;81(3):594-602
17177269
Curr Gene Ther. 2008 Oct;8(5):391-405
18855634
Annu Rev Biochem. 2005;74:711-38
15952901
Eur J Pharm Biopharm. 2008 Jan;68(1):67-73
17888640
Development. 2004 Nov;131(21):5481-90
15469979